Recro Pharma (REPH) Tops Q3 EPS by 2c

Recro Pharma (NASDAQ: REPH) reported Q3 EPS of ($0.19), $0.02 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $20.35 million.

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c